Login to Your Account

Call for Postmarketing CV Studies

Panel’s Hot Air Ends in Yes for Theravance/GSK COPD Bid

By Randy Osborne
Staff Writer

Tuesday, September 10, 2013
Panelists on the FDA’s Pulmonary-Allergy Drugs Advisory Committee that convened to decide about Anoro Ellipta, the inhaler product for chronic obstructive pulmonary disease (COPD), proved harder to satisfy than briefing documents might have led Glaxosmithkline plc (GSK) and partner Theravance Inc. to expect.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription